Generic Name:
pemigatinib
Project Status:
Complete
Therapeutic Area:
Cholangiocarcinoma
Manufacturer:
Incyte Biosciences Canada Corporation
Brand Name:
Pemazyre
Project Line:
Reimbursement Review
Project Number:
PC0252-000
Tumour Type:
Gastrointestinal
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adults with previously treated, unresectable locally advanced or metastatic CCA with a FGFR2 fusion or other rearrangement.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
Gastrointestinal
Indications:
For the treatment of adults with previously treated, unresectable locally advanced or metastatic CCA with a FGFR2 fusion or other rearrangement.
Recommendation Type:
Do not reimburse
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Procedural review:
Status: Concluded.
Description: The procedural review request alleged that Pemazyre had not been considered under the deliberative framework for significant unmet need, as described in the CADTH Procedures for Reimbursement Reviews (the “Procedures”). This matter was concluded following a case conference meeting between CADTH and CGOEN. Mutual agreement was reached that no deviation from the Procedures had occurred for the reimbursement review of Pemazyre.
Outcome: The pERC Final Recommendation of Do Not Reimburse is upheld for Pemazyre.